CRS: Biosimilar competition not likely in the short-term
By Mari Serebrov
Monday, February 3, 2014
With an eye on enhancing biologic competition, the FTC is diving into some of the issues that will shape the biosimilar market in the U.S. But the Congressional Research Service (CRS) isn’t holding its breath as it waits for the competition to hit.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.